Scientific matters can only be clarified by prolonged, faithful bona fide observations in friendly exchange of opinion, never by imprisonment. A person's right to know, to learn, to inquire, to make bona fide errors, to investigate must, by all means, be safe, if the word FREEDOM should ever be more than an empty political slogan.

This inquiry is a current Legislative Council inquiry conducted by the General Purpose Standing Committee No. 4. This Inquiry was established by the Legislative Council on Thursday 22 November 2012 to inquire and report on the use of cannabis for medical purposes.

The Inquiry will examine the efficacy and safety of using cannabis for medical purposes; if and how cannabis should be supplied for medical use; the legal implications and issues concerning the use of cannabis for medical purposes and any other related matters. The Inquiry will examine a range of modes by which the chemical properties of cannabis may be accessed for therapeutic purposes, from smoking of the plant to the manufacturing of pharmaceutical products consumed in nasal sprays, tablet or other forms.

Additionally, evidence suggests that they are reducing the problematic use of opiates, alcohol and other substances in their communities. If we are to ever benefit from drug policies based on science, reason and compassion, national governments will need to abandon the misinformation that underscores drug prohibition, and to start promoting and supporting research into cannabis and cannabinoids as both a relatively safe and effective medicine in the treatment of chronic pain and other serious medical conditions, and as a potential “exit drug” for problematic substance use.

The Single Convention establishes a system of controls in respect to the cultivation of opium poppies and cannabis. In accordance with Articles 23 and 28, parties are required to establish a centralised Government agency to carry out functions in relation to the cultivation of opium poppies and cannabis, and only cultivators licensed by this agency may be authorised to engage in cultivation.

"Nearly all medicines have toxic, potentially lethal effects. But marijuana is not such a substance. There is no record in the extensive medical literature describing a proven, documented cannabis-induced fatality ... Simply stated, researchers have been unable to give animals enough marijuana to induce death ... In practical terms, marijuana cannot induce a lethal response as a result of drug-related toxicity ... In strict medical terms marijuana is far safer than many foods we commonly consume. For example, eating 10 raw potatoes can result in a toxic response. By comparison, its physically impossible to eat enough marijuana to induce death ... Marijuana, in its natural form, is one of the safest therapeutically active substances known to man. By any measure of rational analysis marijuana can be safely used within the supervised routine of medical care ... Marijuana has a currently accepted medical use in treatment in the United States for spasticity resulting from multiple sclerosis and other causes ... It would be unreasonable, arbitrary and capricious for DEA to continue to stand between those sufferers and the benefits of this substance."

In 1988 the first cannabinoid receptor was discovered and since then researchers have learned that there are two different types of cannabinoid receptors which are distributed throughout our bodies and that we make chemicals within our bodies endocannabinoids which are similar to the cannabinoids in the cannabis plant. Both plant and human cannabinoids bind to and influence these receptors in order to discourage the rise and progression of numerous disease processes.

Cannabinoid receptor type-1 (CB1) - CB1 receptors are found primarily in the brain, to be specific in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are absent in the medulla oblongata, the part of the brain stem responsible for respiratory and cardiovascular functions. Thus, there is not the risk of respiratory or cardiovascular failure that can be produced by some drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.

Cannabinoid receptor type-2 (CB2) - CB2 receptors are predominantly found in the immune system, or immune-derived cells with the greatest density in the spleen. While found only in the peripheral nervous system, a report does indicate that CB2 is expressed by a subpopulation of microglia in the human cerebellum. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.

The cannabinoid system is a major neurochemical system whose functional significance has only recently been explored. We are witnessing the beginning of a revolution in cannabinoid research.

The endogenous opioid system and the endocannabinoid system are co-localised in pain-processing regions and opioids and cannabinoids exert a synergistic antinociceptive effect. The ability of cannabinoids to induce antinociception in virtually every animal model of acute or persistent pain evaluated has encouraged researchers to try to better understand this important non-opioid system of analgesia.

There are currently around 80 known/discovered types of cannabinoids. In 2005 research from the University of Mississippi, USA showed cannabis contains 489 identifiable chemical compounds known to exist in the cannabis plant. At least 200 of these are cannabinoids, terpenes and flavonoids which are found in a wide range of concentrations within the flower, leaf, and stem, and which are the basis for medical and scientific use of cannabis. The cannabinoids can serve as appetite stimulants, antiemetics, antispasmodics, and have some analgesic effects.

At least 1 in 5 Australians, that's including children, live with chronic pain. Among people aged over 65, it's 1 in 3. Research shows that chronic pain left untreated leads to devastating effects on the welfare of people's lives, and the longer this goes on untreated the worse it gets. The National Pain Strategy, developed by more than 150 healthcare professionals and consumers at a 2010 national summit, recommended chronic pain be recognised as a priority health issue and constitute a disease in its own right. Yet it remains one of the most neglected areas of healthcare.

Rare disease affects more than 2 million Australians and are defined as a condition, syndrome or disorder that affects 1 in 10,000 people or less and are either life-threatening or chronically debilitating. Many are alone in their plight to tackle and come to terms with an incredibly unique, debilitating and life-threatening illness.

Mullaways Medical Cannabis an Australian Medical Cannabis Company has developed a natural low dose cannabinoid-derived medicine for the treatment of chronic pain which is involved in a range of conditions including endocannabinoid imbalance, cancer treatment, multiple sclerosis, diabetes, terminal illnesses and Crohn's disease. Mullaways Medical Cannabis has cross-bred different types of the plant to produce new strains that could be used to develop cannabinoid medicines to treat a wide range of disorders.

The first of these 'Super breeds' of medicinal cannabinoids developed in Australia, called the Cleverman will be registered with IP Australia who administer Plant Breeder's Rights.

Research Leader and Director Anthony David Bower said, "It has been demonstrated that there are something like 80 cannabinoids in the cannabis plant, and to date only a small number have been looked at in any detail."

Mullaways Medical Cannabis proposes to research and develop other cannabinoid based medicines including patches, creams, oils and edibles that have therapeutic benefits and that may be delivered more safely and effectively than by smoking cannabis.

The company also proposes to conduct research into the different methods of growing the cannabis plant and conduct research into the basic chemistry and pharmacology of cannabinoids with the aim of developing cannabinoid based medicines of an acceptable standard that may be delivered more safely and effectively than by smoking cannabis.

The Greens' John Kaye Talks Medicinal Cannabis The objective is to get a motion through the Upper House that calls on Minister for Health Jillian Skinner to conduct a trial of the therapeutic and palliative benefits of medicinal cannabis. The Minister has the legislative power to conduct a trial. Given that this was a recommendation at the 1999 Drug Summit, we think a motion is enough to push the Minister over the line and do what should have happened 13 years ago. Complete Interview of "Calls for medicinal marijuana" “It is clear that in the case of Mr Bower road blocks have been thrown up that would not have been there if he had been a multinational pharmaceutical company or the primary seedstock were not related to a recreational drug," Greens MP John Kaye said.

Preliminary Design Work has been completed for the Kempsey manufacturing plant, designed to process 1 metric tonne of cannabis a week into Tincture. Mullaways Medical Cannabis has had a number of meetings with representatives from WILEY & CO PTY LTD concerning the construction of the manufacturing plant. WILEY & CO PTY LTD

The Resin recovered from the CLEVERMAN variety is recovered as THCA, Non-Psychotropic. This can then be used to produce a Tincture with the required Properties to restore health and enough Psychotropic Response to assist with the relief of chronic pain.

The Recovered Resin can be used to make the following range of Medical Cannabis Products;

SAFE Medical Cannabis Products can now be designed, with Cannabis cultivated to produce the required mixture of Cannabinoids for the Treatment.

4 THC thresholds for psychotropic effects

However, nearly one half (41%) experienced conditions or symptoms that were not helped by its use. The most prevalent concerns related to its illegality. Participants reported strong support for their use from clinicians and family. There was almost universal interest (89%) in participating in a clinical trial of medical cannabis, and strong support (79%) for investigating alternative delivery methods.

With regard to Childhood Sexual Abuse and its association with psychosis, research has consistently found high rates of sexual abuse in childhood within psychotic populations. In fact, a number of studies have provided important evidence in support of a causal relationship between child abuse and psychosis; however, no main effect was found within this sample. One explanation of this may be that incidents of Childhood Sexual Abuse have been underreported because, although general population data was used in this study, evidence suggests that psychiatric patients underreport rather than overreport abuse......

How much THCA or THC is required to produce Pain Relief?
Tincture

Vaporiser

Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain

Vaporisers